GleamWall
中文EN

ADAPY Adaptimmune Therapeutics PLC

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1621227 · Fiscal year ends 12/31

Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-54.0%
TTM net income YoY-134.1%
TTM EPS YoY-83.3%
Revenue 3-yr CAGR77.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-252.3%
Net margin-260.8%
FCF margin-294.5%
EBITDA margin-237.0%

Returns

ROE-1,341.1%
ROA-75.1%
ROIC (approx.)—
Asset turnover0.29x

Leverage & solvency

Liabilities / assets154.3%
Debt / equity—
Current ratio1.52x
Interest coverage-28.99x

Cash quality & payout

Operating cash flow / net income1.12x
Accruals ratio9.0%
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242024-12-31FY20232023-12-31
Income statement
Revenue$178.03M$60.28M
Cost of revenue$70,000—
Gross profit$177.96M—
R&D expense$149.06M$126.51M
SG&A expense$87.26M$73.51M
Operating income-$68.76M-$139.74M
Interest expense$3.35M—
Pretax income-$67.24M-$112.53M
Income tax$3.58M$1.34M
Net income-$70.81M-$113.87M
EBITDA-$57.95M-$130.29M
EPS (basic)-0.05-0.09
EPS (diluted)-0.05-0.09
Weighted avg. shares (diluted)1.51B1.21B
Balance sheet
Cash & equivalents$91.14M$147.02M
Short-term investments$60.47M$2.95M
Receivables$1.45M$821,000
Inventory$7.32M—
Current assets$188.17M$207.55M
PP&E, net$31.31M$50.95M
Intangibles$3.88M$330,000
Total assets$245.96M$282.62M
Current liabilities$64.53M$72.79M
Long-term debt$50.24M—
Total debt$50.24M—
Total liabilities$234.11M$243.10M
Shareholders' equity$11.85M$39.51M
Net debt-$40.90M—
Shares outstanding1.54B1.36B
Cash flow statement
Operating cash flow-$73.21M-$140.88M
Capital expenditure$886,000$4.68M
Free cash flow-$74.09M-$145.56M
Investing cash flow-$58.95M$176.54M
Financing cash flow$78.75M$880,000
Depreciation & amortization$10.81M$9.45M
Stock-based compensation$12.05M$11.77M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.